BridgeBio Pharma, Inc. BBIO

Health CarePharmaceuticalsUnited States of America

Last close 75.00 USD on Nov 2, 2026, −2.0% year to date

Quant rating

Quant rating C Rank 230 of 565 in Health Care

Growth A 25 of 565
Valuation C 372 of 565
Quality B 102 of 565
Revisions D 536 of 565
Momentum B 172 of 565

Wall Street consensus Buy (1.91)Average target 106.69 USD +42.3%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 14.6B
Enterprise value: 17.4B
52-week range: 60.23 – 93.31
3-year range: 22.35 – 93.31
Dividend yield: –
Beta (5 years): 0.94
Shares outstanding: 195M
Next earnings: Feb 22, 2027

About the company

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Growth and profitability

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	502	222	9.3	77.6	69.7	–
Revenue growth	126.3%	2,285.3%	−88.0%	11.4%	745.1%	127.4%
EPS (basic, normalized)	−3.78	−2.88	−3.95	−3.26	−3.90	–
EPS growth	–	–	–	–	–	–
Gross margin	95.8%	98.3%	73.7%	95.6%	95.5%	91.8%
Net margin	−144.4%	−241.4%	−6,913.9%	−619.7%	−806.9%	−1,745.3%
ROE	–	–	–	–	–	–

Balance sheet, last quarter
Cash & short-term investments (mil)	1,539
Current ratio	2.09x
Long-term debt (mil)	2,813
Net debt (mil)	2,774
Total equity (mil)	−1,662
Net debt / equity	−1.67x
Net debt / EBITDA	−5.36x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	502	+126.3%	34.6x	−518	+6.8%	−33.6x	−3.78	−31.2%	−19.8x
2026	1,088	+116.8%	16.0x	−330	+36.2%	−52.6x	−2.58	+31.7%	−29.1x
2027	1,671	+53.5%	10.4x	124	+137.4%	140.7x	−0.41	+84.0%	−181.7x
2028	2,551	+52.7%	6.8x	641	+419.0%	27.1x	3.43	+931.9%	21.8x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	1,088	+5.6%	+12.9%	+18.1%	−2.58	+1.8%	−17.1%	−32.9%
2027	1,671	−3.2%	+1.5%	+3.2%	−0.41	−2,370.6%	−166.3%	−157.2%
2028	2,551	−1.7%	+3.6%	+6.5%	3.43	−6.4%	−14.3%	−7.6%

Earnings surprises

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	211	2.2	2.7	5.9	117	111	121	154	195	244
Sales mean (mil)	14.0	3.6	3.8	3.5	61.9	91.4	106	147	178	219
Surprise	+1,404.4%	−39.3%	−27.4%	+69.1%	+88.3%	+21.0%	+13.5%	+5.0%	+9.3%	+11.4%
EPS reported	−0.20	−0.39	−1.10	−1.40	−0.88	−0.95	−0.95	−1.00	−0.84	−0.78
EPS mean	−0.76	−1.06	−0.98	−1.13	−0.92	−0.84	−0.89	−0.74	−0.68	−0.58
Surprise	+73.8%	+63.3%	−12.4%	−23.8%	+4.7%	−12.6%	−6.9%	−34.7%	−23.8%	−33.7%

Peer comparison Pharmaceuticals

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
BBIO BridgeBio Pharma, Inc.	14.6B	−5.36x	−144.4%	−9.13x	−29.1x	−181.7x	−52.6x	140.7x
AMGN Amgen Inc	251.6B	2.03x	21.0%	21.53x	20.2x	19.0x	13.6x	13.1x
VRTX Vertex Pharmaceuticals Incorporated	140.2B	−1.44x	32.9%	6.92x	29.5x	26.4x	23.3x	20.6x
MRNA Moderna, Inc.	88.2B	1.58x	−145.2%	13.03x	−26.2x	−46.0x	−25.6x	−47.3x
REGN Regeneron Pharmaceuticals, Inc.	99.4B	−1.26x	31.7%	3.06x	14.5x	13.7x	12.2x	11.1x
BIIB Biogen Inc.	36.8B	2.02x	13.1%	1.95x	19.9x	15.6x	15.5x	12.6x
Mean		−0.40x	−31.8%	6.23x	4.8x	−25.5x	−2.3x	25.1x
Median		0.16x	17.0%	4.99x	17.2x	14.7x	12.9x	12.9x

Technical analysis

1M+11.5%
3M−6.4%
1Y+19.7%
3Y+178.6%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, BridgeBio Pharma, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	502	222	9.3	77.6	69.7	8.2
Cost of revenue	21.0	3.9	2.4	3.4	3.1	0
Gross profit	481	218	6.9	74.2	66.6	8.2
Selling, general & administrative expenses	531	289	151	143	192	146
Research & development	452	506	456	399	451	337
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	42.5	−136	7.9	43.8	–	–
Other operating expenses	0	0	0	0	0	0
Operating income	−545	−441	−607	−512	−577	−474
Net interest income (expense)	−231	−105	−44.9	35.0	−45.6	−32.6
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	43.1	4.1	−0.9	−7.5	35.8	1.6
Net income before taxes	−733	−542	−653	−485	−586	−505
Provision for taxes	0.4	1.2	–	–	–	–
Minority interest	8.0	7.6	10.0	3.5	23.9	56.8
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−725	−536	−643	−481	−563	−449
Extraordinary items	–	–	–	–	–	–
Net income	−725	−536	−643	−481	−563	−449
EBIT, normalized	−502	−577	−599	−468	−577	−474
EBITDA, normalized	−497	−571	−593	−462	−571	–
Basic EPS, normalized	−3.78	−2.88	−3.95	−3.26	−3.90	–

Balance sheet in millions of USD, fiscal years

Balance sheet, BridgeBio Pharma, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	587	681	435	472	837	607
Receivables	139	4.7	1.8	17.1	19.7	–
Total inventory	26.8	–	–	–	–	–
Prepaid expenses	43.5	34.7	24.3	21.9	32.3	35.6
Other current assets	0.6	0.1	16.7	37.9	0.2	0.1
Total current assets	798	721	478	549	889	643
Property, plant & equipment	13.5	12.8	19.8	25.2	46.0	36.8
Goodwill	–	–	–	–	–	–
Intangibles	28.1	23.9	26.3	28.7	44.9	–
Long-term investments	80.0	144	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	16.7	18.2	22.6	20.2	33.0	23.9
Total assets	936	919	546	623	1,013	704
Liabilities
Accounts payable	36.2	9.6	10.7	11.6	11.9	8.9
Payable/accrued	–	–	–	–	–	–
Accrued expenses	233	130	127	102	123	79.6
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	–	–	–	–	0.3	1.6
Other current liabilities	18.4	14.6	6.1	8.2	0	5.5
Total current liabilities	288	154	144	121	135	95.6
Long-term debt	2,708	2,200	1,727	1,708	1,705	477
Minority interest	10.0	10.3	11.7	9.7	4.8	50.0
Other liabilities	17.1	22.1	18.3	38.9	38.3	22.6
Total liabilities	3,023	2,387	1,901	1,878	1,883	646
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.2	0.2	0.2	0.2	0.2	0.1
Additional paid-in capital	2,058	1,903	1,481	939	842	1,021
Retained earnings (accumulated deficit)	−3,821	−3,096	−2,561	−1,918	−1,437	−889
Treasury stock	−323	−275	−275	−275	−275	−75.0
Other equity	0	0	0	−0.3	−0.1	0.2
Total equity	−2,087	−1,468	−1,354	−1,255	−870	57.9
Total liabilities & shareholders' equity	936	919	546	623	1,013	704

Cash flow statement in millions of USD, fiscal years

Cash flow statement, BridgeBio Pharma, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	−733	−543	−653	−485	−586	−505
Depreciation, depletion & amortization	5.4	6.1	6.5	6.8	5.8	–
Deferred taxes	–	–	–	–	–	–
Non-cash items	333	−15.5	114	24.0	83.7	90.8
Changes in working capital	−51.1	32.0	5.1	34.3	−1.1	14.9
Cash from operations	−446	−521	−528	−419	−498	−400
Investing activities
Capital expenditures	−9.6	−8.9	−1.3	−6.3	−13.2	−7.5
Other investing cash flows	−14.9	69.7	55.3	459	−188	−45.5
Cash from investing	−24.5	60.8	54.0	453	−201	−53.0
Financing activities
Financing cash flow items	257	−7.5	−7.7	−0.7	−164	−41.9
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	102	756	459	−12.4	900	489
Cash from financing	359	748	452	−13.1	736	447
Foreign exchange effects	–	–	–	–	–	–
Net change in cash	−111	289	−22.2	20.5	37.7	−5.5
Free cash flow	−456	−530	−529	−426	−511	−407

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.